• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Precision medicine meets public health: population screening for BRCA1 and BRCA2.

作者信息

Levy-Lahad Ephrat, Lahad Amnon, King Mary-Claire

机构信息

Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel (ELL); Faculty of Medicine, Hebrew University Medical School, Jerusalem, Israel (ELL, AL); Department of Family Medicine, Clalit Health Services, Jerusalem, Israel (AL); Department of Medicine and Department of Genome Sciences, University of Washington, Seattle, WA (MCK).

出版信息

J Natl Cancer Inst. 2014 Dec 30;107(1):420. doi: 10.1093/jnci/dju420. Print 2015 Jan.

DOI:10.1093/jnci/dju420
PMID:25550384
Abstract
摘要

相似文献

1
Precision medicine meets public health: population screening for BRCA1 and BRCA2.精准医学与公共卫生相遇：BRCA1和BRCA2的人群筛查
J Natl Cancer Inst. 2014 Dec 30;107(1):420. doi: 10.1093/jnci/dju420. Print 2015 Jan.
2
Unknown significance.意义不明。
Science. 2014 Dec 5;346(6214):1167-70. doi: 10.1126/science.346.6214.1167.
3
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.携带BRCA1和BRCA2突变的阿什肯纳兹犹太女性患卵巢癌的风险。
Clin Cancer Res. 2002 Dec;8(12):3776-81.
4
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.BRCA1 和 BRCA2 家族乳腺癌、卵巢癌和对侧乳腺癌的外显率：老年时癌症发病率高。
Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4.
5
[Genetic testing in patients at risk for carcinoma of the breast].[乳腺癌高危患者的基因检测]
Dtsch Med Wochenschr. 2006 Oct 27;131(43):2420-2. doi: 10.1055/s-2006-955026.
6
Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence.
Genet Med. 2009 Sep;11(9):620-1. doi: 10.1097/GIM.0b013e3181b765d3.
7
Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.犹太裔 BRCA1 和 BRCA2 基因突变携带者的癌症风险：口服避孕药使用和突变来源的影响。
Breast Cancer Res Treat. 2011 Sep;129(2):557-63. doi: 10.1007/s10549-011-1509-z. Epub 2011 Apr 16.
8
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.在阿什肯纳兹族乳腺癌和卵巢癌家族中未发现基因组 BRCA1 和 BRCA2 重排。
Breast Cancer Res Treat. 2010 Sep;123(2):581-5. doi: 10.1007/s10549-010-0818-y. Epub 2010 Mar 11.
9
Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.BRCA1 突变携带者行预防性输卵管卵巢切除术的经验及遗传性乳腺癌卵巢癌综合征预防性手术体系在日本的建立：我们未来的挑战。
Jpn J Clin Oncol. 2013 May;43(5):515-9. doi: 10.1093/jjco/hyt036. Epub 2013 Mar 13.
10
BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.携带BRCA1和BRCA2基因突变者作为化学预防试验的潜在候选对象。
J Cell Biochem Suppl. 2000;34:13-8.

引用本文的文献

1
Secondary (additional) findings from the 100,000 Genomes Project: Disease manifestation, health care outcomes, and costs of disclosure.来自“十万基因组计划”的次要（额外）发现：疾病表现、医疗保健结果及披露成本。
Genet Med. 2024 Mar;26(3):101051. doi: 10.1016/j.gim.2023.101051. Epub 2023 Dec 19.
2
Insights from 25 years of oncogenetics: one person's perspective.25年肿瘤遗传学研究的见解：个人观点
Front Genet. 2023 May 12;14:1180879. doi: 10.3389/fgene.2023.1180879. eCollection 2023.
3
Implementation of a Population-Based Cancer Family History Screening Program for Lynch Syndrome.
基于人群的林奇综合征癌症家族史筛查项目的实施。
Cancer Control. 2023 Jan-Dec;30:10732748231175011. doi: 10.1177/10732748231175011.
4
Is Regulated by the Transcription Factor , and Its Silencing Promotes Neural Differentiation in Retinal Neurons.其表达受到转录因子 的调控，其沉默促进视网膜神经元的神经分化。
Int J Mol Sci. 2022 Nov 10;23(22):13860. doi: 10.3390/ijms232213860.
5
Predominance of Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with or Mutation.未选择的伴有或不伴有突变的乳腺癌中突变及雌激素受体阳性的优势情况
Cancers (Basel). 2022 Jul 4;14(13):3266. doi: 10.3390/cancers14133266.
6
Uptake of genetic counseling and testing in a clinic-based population of women with breast cancer.基于诊所的乳腺癌女性群体中遗传咨询和检测的应用。
Cancer Med. 2022 Sep;11(17):3304-3311. doi: 10.1002/cam4.4684. Epub 2022 Mar 23.
7
Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.基于网络医疗模式的阿什肯纳兹犹太人群 BRCA1/2 靶向筛查：一项观察性队列研究。
Genet Med. 2022 Mar;24(3):564-575. doi: 10.1016/j.gim.2021.10.016. Epub 2021 Dec 3.
8
Revisiting Secondary Information Related to Pharmacogenetic Testing.重新审视与药物遗传学检测相关的二级信息。
Front Genet. 2021 Oct 1;12:741395. doi: 10.3389/fgene.2021.741395. eCollection 2021.
9
Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.印度北部一家三级护理中心连续治疗的乳腺癌患者的致病突变特征及种系基因检测标准评估。
Ann Surg Oncol. 2022 Feb;29(2):1423-1432. doi: 10.1245/s10434-021-10870-w. Epub 2021 Oct 2.
10
Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!扩大对乳腺癌种系致病变异的搜索范围。我们应该走多远，又该跳多高？错失的机会！
Oncol Rev. 2021 Jun 24;15(1):544. doi: 10.4081/oncol.2021.544. eCollection 2021 Feb 26.